Calcitonin Gene-Related Peptide Effects on Phenotype and IL-12 Production of Monocyte-Derived Dendritic Cells in Rheumatoid Arthritis Patients

Document Type: Original Article


1 Immunology Research Center, BuAli Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran

2 Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran


Recent studies on human indicate that the introduction of therapeutic use of tolerogenic dendritic cell (DC) for chronic inflammatory conditions is imminent. For the purpose of defining CGRP potency in tolerogenic DC production, we investigated the phenotype and IL-'2 production of DCs generated from the monocytes of rheumatoid arthritis (RA) patients in the presence of the calcitonin gene-related peptide (CGRP), as a multifunctional neuropeptide.
Materials and Methods
DCs were generated from isolated monocytes from four resistant and two early female RA patients using IL- 4, GM-CSF, and CGRP at concentrations of 0, ', and '00 nM. Then, the phenotype of neuropeptide-treated or untreated DCs was determined using flow cytometry and the IL-'2 production was measured by ELISA.
Our study showed that, on the last day of the culture, at a concentration of ' nM CGRP, the mean fluorescence intensity (MFI) for CD80 increased ('4.'3%) and the MFIs for CD83, CD86, and HLA-DR decreased ('4.57%, 5.28%, and 6.88% respectively). Moreover, at '00 nM CGRP concentration, the MFI for CD80 increased (''.'0%) and the MFIs for CD83, CD86, and HLA-DR decreased (4.27%, '8.60%, and '9.75% respectively). In addition, our results indicated that the mean concentrations of IL-'2 produced at 0, ', and '00 nm CGRP concentrations measured '3.72±2.4', ''.0'±'.6', and 7±'.34 pg/ml respectively.
Decreased CD83, CD86, and HLA-DR expression and reduced IL-'2 production by CGRP were found in the RA patients' monocyte-derived DCs. CD83 is a well-defined DC activation marker. HLA-DR and CD86 are appropriate molecules for inducing an immune response. IL-'2 promotes cell-mediated immunity. Therefore we suggest that CGRP may be used as an inducer in the production of tolerogenic DCs.


1.Kavanaugh A. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol 2007; 21:929-942.

2.Lutzky V, Hannawi S, Thomas R. Cells of the synovium in rheumatoid arthritis. Dendritic cells. Arthritis Res Ther 2007: 9:219.

3.Firestein GS. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 2005; 11:S39-44.

4.Panayi GS, Corrigall VM. BiP, an anti-inflammatory ER protein, is a potential new therapy for the treatment of rheumatoid arthritis. Novartis Found Symp 2008; 291:212-216.

5.Yamaoka K, Tanaka Y. Jak inhibitor; possibility and mechanism as a new disease modifying anti-rheumatic drug. Nihon Rinsho Meneki Gakkai Kaishi 2009; 32:85-91.

6.Rossi M,Young JW.Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol 2005; 175:1373-1381.

7.Steinbrink K, Mahnke K, Grabbe S, Enk AH, Jonuleit H. Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance? Hum Immunol 2009; 70:289-293.

8.Thomson AW, Robbins PD. Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann Rheum Dis 2008; 67:iii90-96.

9.Manfred B, Lutz GS. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002; 23:445-451.

10.Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7:610-621.

11.Taub DD. Neuroendocrine interactions in the immune system. Cell Immunol 2008; 252:1-6.

12.Wang H, Xing L, Li W, Hou L, Guo J, Wang X. Production and secretion of calcitonin gene-related peptide from human lymphocytes. J Neuroimmunol 2002; 130:155-162.

13.Harzenetter, MD, Novotny AR, Gais P, Molina CA, Altmayr F, Holzmann B. Negative regulation of TLR responses by the neuropeptide CGRP is mediated by the transcriptional repressor ICER. J Immunol 2007; 179:607-615.

14.Gomes RN, Castro-Faria-Neto HC, Bozza PT, Soares MB, Shoemaker CB, David JR, et al. Calcitonin gene- related peptide inhibits local acute inflammation and protects mice against lethal endotoxemia. Shock 2005; 24:590-594.

15.Bracci-Laudiero L, Aloe L, Buanne P, Finn A, Stenfors C, Vigneti E, et al. NGF modulates CGRP synthesis in human B-lymphocytes: a possible anti-inflammatory action of NGF? J Neuroimmunol 2002; 123:58-65.

16.Fox FE, Kubin M, Cassin M, Niu Z, Hosoi J, Torii H, et al. Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. J Invest Dermatol 1997; 108:43-48.

17.Torii H, Hosoi J, Beissert S, Xu S, Fox FE, Asahina A, et al. Regulation of cytokine expression in macrophages and the Langerhans cell-like line XS52 by calcitonin gene-related peptide. J Leukoc Biol 1997; 61:216-223.

18.Reyes-Garcia MG, Garcia-Tamayo F. A neurotransmitter system that regulates macrophage pro-inflammatory functions. J Neuroimmunol 2009; 216:20-30. 

19.Carucci JA, Ignatius R, Wei Y, Cypess AM, Schaer DA, Pope M, et al. Calcitonin gene-related peptide decreases expression of HLA-DR and CD86 by human dendritic cells and dampens dendritic cell-driven T cell- proliferative responses via the type I calcitonin gene-related peptide receptor. J Immunol 2000; 164:3494-3499.

20.Seiffert K, Granstein RD. Neuroendocrine regulation of skin dendritic cells. Ann N Y Acad Sci 2006; 1088:195-206.

21.Bulloch K,McEwen BS, Nordberg J, Diwa A, Baird S. Selective regulation of T-cell development and function by calcitonin gene-related peptide in thymus and spleen. An example of differential regional regulation of immunity by the neuroendocrine system. Ann N Y Acad Sci 1998; 840:551-62.

22.Talme T, Liu Z, Sundqvist KG. The neuropeptide calcitonin gene-related peptide (CGRP) stimulates T cell migration into collagen matrices. J Neuroimmunol 2008; 196:60-66.

23.Schlomer JJ,Storey BB,Ciornei RT,McGillis JP. Calcitonin gene-related peptide inhibits early B cell development in vivo. J Leukoc Biol 2007; 81:802-808.

24.Foreman JC. Substance P and calcitonin gene-related peptide: effects on mast cells and in human skin. Int Arch Allergy Appl Immunol 1987; 82:366-371.

25.Springer J, Geppetti P, Fischer A, Groneberg DA. Calcitonin gene-related peptide as inflammatory mediator. Pulm Pharmacol Ther 2003; 16:121-130.

26.Eysselein VE, Reinshagen M, Patel A, Davis W, Nast C, Sternini C. Calcitonin gene-related peptide in inflammatory bowel disease and experimentally induced colitis. Ann N Y Acad Sci 1992; 657:319-327.

27.Kroeger I, Erhardt A, Abt D, Fischer M, Biburger M, Rau T, et al. The neuropeptide calcitonin gene-related peptide (CGRP) prevents inflammatory liver injury in mice. J Hepatol 2009; 51:342-353.

28.Tang Y, Feng Y, Wang X. Calcitonin gene-related peptide potentiates LPS-induced IL-6 release from mouse peritoneal macrophages. J Neuroimmunol 1998; 84:207-212.

29.Liu J, Chen M, Wang X. Calcitonin gene-related peptide-enhanced nitric oxide release and inducible NOS activity and mRNA expression in LPS-stimulated mouse peritoneal macrophages. Shock 2001;16:64-69.

30.Yaraee R,Ebtekar M, Ahmadiani A, Sabahi F. Neuropeptides (SP and CGRP) augment pro-inflammatory cytokine production in HSV-infected macrophages. Int Immunopharmacol 2003; 3:1883-1887.

31.Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-1118.

32.Eskandari F,Webster JI, Sternberg EM. Neural immune pathways and their connection to inflammatory diseases. Arthritis Res Ther 2003; 5:251-265.

33.Jara LJ, Navarro C, Medina G, Vera-Lastra O, Blaanco F. Immune-neuroendocrine interactions and autoimmune diseases. Clin Dev Immunol 2006; 13:109-123.

34.Ghatta S, Nimmagadda D, Calcitonin gene-related peptide: Understanding its role. Indian Jf Pharmacol 2004; 36:277.

35.Nong YH, Titus RG, Ribeiro JM, Remold HG. Peptides encoded by the calcitonin gene inhibit macrophage function. J Immunol 1989; 143:45-49.

36.Cao W, Lee SH, Lu J. CD83 is preformed inside monocytes, macrophages and dendritic cells, but it is only stably expressed on activated dendritic cells. Biochem J 2005; 385:85-93.

37.Prechtel AT, Steinkasserer A.CD83: an update on functions and prospects of the maturation marker of dendritic cells. Arch Dermatol Res 2007; 299:59-69.

38.Sansom DM, Manzotti CN, Zheng Y.What's the difference between CD80 and CD86? Trends Immunol 2003; 24:314-319.

39.Perez N, Karumuthil Melethil S, Li R, Praabhakar BS, Holterman MJ, Vasu C. Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1 (+) -adaptive regulatory T cell generation. J Immunol 2008; 180:6566-6576.

40.Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322:271-275.

41.Salek-Ardakani S, Arens R, Flynn R,Sette A, Schoenbereger SP, Croft M. Preferential use of B7.2 and not B7.1 in priming of vaccinia virus-specific CD8 T cells. J Immunol 2009; 182:2909-2918.

42.Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002; 277:7766-7775.

43.Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711.

44.Capellino S, Straub RH. Neuroendocrine immune pathways in chronic arthritis. Best Pract Res Clin Rheumatol 2008; 22:285-297.